The Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) is scheduled to meet on Thursday to evaluate the potential modification of the COVID-19 vaccine to target the XFG subvariant for the 2026-2027 respiratory viral season.
✓ AI-Debiased Article
10
Wire-neutral
provisional
✓ No loaded language, vague sourcing, or framing detected.
FDA Advisory Committee to Discuss Updated COVID Vaccine for XFG Subvariant
The FDA's advisory committee will convene to discuss the possibility of updating the COVID-19 vaccine to address the XFG subvariant. The meeting is set for Thursday, May 28, 2026.
Annotating as
No note attached
on this article.
Original vs. Neutral
Original Headline
FDA advisers to weigh updated COVID vaccine targeting XFG subvariant
Neutral Headline
FDA Advisory Committee to Discuss Updated COVID Vaccine for XFG Subvariant